Rajotte et al.
10. Jegede O, Khodyakova A, Chernov M, Weber J, Menéndez-Arias L,
Gudkov A, Quiñones-Mateu ME. 2011. Identification of low-molecular
weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-
throughput screening system. Antiviral Res. 91:94–98.
11. Jochmans D, Van Schoubroeck B, Ivens T, Dehertogh P, Kesteleyn B,
Hertogs K. 2005. ATP enhances the inhibitory effect of NcRTIs (nucleo-
tide competing RT inhibitors). Antivir. Ther. 10(Suppl 1):A83.
12. Jochmans D. 2008. Novel HIV-1 reverse transcriptase inhibitors. Virus
Res. 134:171–185.
inhibitors with a novel mechanism of action: NNRTIs that compete with
the nucleotide substrate. Viruses 2:880–899.
23. Freisz S, Bec G, Radi M, Wolff P, Crespan E, Angeli L, Dumas P, Maga
G, Botta M, Ennifar E. 2010. Crystal structure of HIV-1 reverse trans-
criptase bound to a non-nucleoside inhibitor with a novel mechanism of
action. Angew. Chem. 49:1–5.
24. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2001. Selective excision
of AZTMP by drug-resistant human immunodeficiency virus reverse
transcriptase. J. Virol. 75:4832–4842.
13. Götte M, Rausch JW, Marchand B, Sarafianos S, Le Grice SFJ. 2010.
Reverse transcriptase in motion: conformational dynamics of enzyme-
substrate interactions. Biochim. Biophys. Acta 1804:1202–1212.
14. Miller MD. 2004. K65R, TAMs and tenofovir. AIDS Rev. 6:22–33.
15. Di Re M, Sembongi H, He J, Reyes A, Yasukawa T, Martinsson P, Bailey
LJ, Goffart S, Boyd-Kirkup JD, Wong TS, Fersht AR, Spelbrink JN, Holt
IJ. 2009. The accessory subunit of mitochondrial DNA polymerase ␥ de-
termines the DNA content of mitochondrial nucleoids in human cultured
cells. Nucleic Acids Res. 37:5701–5713.
16. Lee YS, Dexter Kennedy W, Whitney Yin Y. 2009. Structural insight into
processive human mitochondrial DNA synthesis and disease-related poly-
merase mutations. Cell 139:312–324.
17. Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW, Germany
JM, Secrist JA III, Vincell R, Shannon WM. 1991. Mechanism of inhi-
bition of human immunodeficiency virus type 1 reverse transcriptase and
human DNA polymerases ␣,  and ␥ by the 5=-triphosphates of carbovir,
3=-Azido-3=-deoxythymidine,2=,3=-dideoxyguanosine, and 3=-
deoxythymidine. J. Biol. Chem. 266:1754–1762.
25. Ehteshami M, Nijhuis M, Ablenas C, Bernatchez J, McCormick S, De
Jong TMC, Jochmans DD, Götte M. 2012. Plasticity of the ATP binding
site of HIV-1 RT promotes binding of both INDOPY-1 and its ATP en-
hancer to the post-translocated complex. Antiviral Ther. 17(Suppl 1):A54.
26. Das K, Sarafianos SG, Arthur Clark DAD, Boyer PL, Hughes SH,
Arnold E. 2007. Crystal structures of clinically relevant Lys103Asn/
Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with
ATP and non-nucleoside Inhibitor HBY 097. J. Mol. Biol. 365:77–89.
27. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H,
Masquelier B. 2006. HIV-1 reverse transcriptase (RT) genotypic patterns
and treatment characteristics associated with the K65R RT mutation. HIV
Med. 7:294–298.
28. Coutsinos D, Invernizzi CF, Moisi D, Maureen Oliveira M, Martinez-
Cajas JL, Bluma G. Brenner BG, Wainberg MA. 2011. A template-
dependent dislocation mechanism potentiates K65R reverse transcriptase
mutation development in subtype C variants of HIV-1. PLoS One
29. Das K, Rajiv Bandwar PRP, White KL, Feng JY, Sarafianos SG, Tuske
S, Tu X, Clark AD, Jr, Boyer PL, Hou X, Gaffney BL, Jones RA, Miller
MD, Hughes SH, Arnold E. 2009. Structural basis for the role of the K65R
mutation in HIV-1 reverse transcriptase polymerization, excision antag-
onism, and tenofovir resistance. J. Biol. Chem. 284:35092–35100.
30. Sharma B, Kaushik N, Singh K, Kumar S, Pandey VN. 2002. Substitu-
tion of conserved hydrophobic residues in motifs B and C of HIV-1 RT
alters the geometry of its catalytic pocket. Biochemistry 41:15685–15697.
31. Petruska J, Sowers LC, Goodman MF. 1986. Comparison of nucleotide
interactions in water, proteins, and vacuum: model for DNA polymerase
fidelity. Proc. Natl. Acad. Sci. U. S. A. 83:1559–1562.
32. Sturino CF, Bousquet Y, James CA, DeRoy P, Duplessis M, Edwards PJ,
Halmos T, Minville J, Morency L, Morin S, Thavonekham B, Tremblay
M, Duan J, Ribadeneira M, Garneau M, Pelletier A, Tremblay S,
Lamorte L, Bethell R, Cordingley MG, Rajotte D, Simoneau B. Identi-
fication of potent and orally bioavailable nucleotide competing reverse
transcriptase inhibitors; in vitro and in vivo optimization of a series of
benzofurano[3,2-d]pyrimidin-2-one derived inhibitors. Bioorg. Med.
Chem. Lett., in press.
18. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996.
Second locus involved in human immunodeficiency virus type 1 resis-
tance to protease inhibitors. J. Virol. 70:3763–3769.
19. Lemke CT, Titolo S, von Schwedler U, Goudreau N, Mercier JF,
Wardrop E, Faucher AM, Coulombe R, Banik SS, Fader L, Gagnon A,
Kawai SH, Rancourt J, Tremblay M, Yoakim C, Simoneau B, Archam-
bault J, Sundquist WI, Mason SW. 2012. Distinct effects of two HIV-1
capsid assembly inhibitor famillies that bind the same site within the N-
terminal domain of the viral CA protein. J. Virol. 86:6643–6655.
20. Lansdon EB, Samuel D, Lagpacan L, Brendza KM, White KL, Hung M,
Liu X, Boojamra CG, Mackman RL, Cihlar T, Ray AS, McGrath ME,
Swaminathan S. 2010. Visualizing the molecular interactions of a nucle-
otide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J.
Mol. Biol. 397:967–978.
21. Maga G, Radi M, Zanoli S, Manetti F, Cancia R, Hübscher U, Spadari
S, Falciani C, Terrazas M, Vilarrasa J, Botta M. 2007. Discovery of
non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with
the nucleotide substrate. Angew. Chem. 46:1810–1813.
22. Maga G, Radi M, Gerard MA, Botta M, Ennifar E. 2010. HIV-1 RT
Antimicrobial Agents and Chemotherapy